Orlagh McGarrity
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Orlagh McGarrity has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Vora
Department of Haematology, Great Ormond Street Hospital, London, United Kingdom
1 shared publication Alasdair Bamford
Paediatric Infectious Diseases
1 shared publication- Alasdair Bamford
UCL Innovative Clinical Trials Unit (former MRC CTU at UCL), Institute of Clinical Trials and Methodology, University College London , London
1 shared publication Angus Hodder
Department of Haematology and Bone Marrow Transplantation, and
1 shared publicationArnold Awuah
Department of Immunology, Great Ormond Street Hospital, London, United Kingdom
1 shared publicationBairavi Indrakumar
Department of Pharmacy, Great Ormond Street Hospital for Children , London
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (11)
A unified population pharmacokinetic model of amikacin in paediatric patients from birth to 18 years for model-informed precision dosing
Background: Amikacin is widely used in paediatric patients, but developmental changes in drug disposition from birth through to adolescence make dose optimization challenging. Existing population pharmacokinetic (PopPK) models are typically developed for specific paediatric age groups, limiting their applicability across the full paediatric age range. Objectives: To develop a unified paediatric PopPK model of amikacin capable of predicting drug concentrations from birth to 18 years of age and to evaluate its suitability for model-informed dosing. Methods: Retrospective therapeutic drug monitoring data were obtained from 409 paediatric patients receiving intravenous amikacin at a tertiary children's hospital. A PopPK model was developed using data from 204 neonates, which incorporated mechanistic covariates describing growth and renal maturation, including allometric body-weight scaling, postmenstrual age (PMA), postnatal age (PNA) and age-adjusted serum creatinine. Predictive performance was evaluated for 205 older patients aged 1 month to 18 years, and compared with previously published paediatric amikacin PopPK models. The model developed using the neonatal data was subsequently refitted to the combined dataset to obtain the final parameter estimates. Results: A two-compartment model adequately described amikacin pharmacokinetics. Clearance was influenced by body weight, PMA, PNA, age-adjusted serum creatinine and concomitant glycopeptide use. The model developed in neonates using mechanistic maturation and renal function covariates successfully predicted amikacin concentrations in older paediatric patients and showed lower prediction bias and improved precision than previously published paediatric amikacin models. The final parameter estimates were obtained by fitting the model developed on neonates to all patients. Conclusions: A maturation-informed PopPK model successfully predicted amikacin concentrations from birth to 18 years and provides a unified framework for model-informed precision dosing across the paediatric age range.
- 6 October 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (11)
Open AccessA unified population pharmacokinetic model of amikacin in paediatric patients from birth to 18 years for model-informed precision dosing
Background: Amikacin is widely used in paediatric patients, but developmental changes in drug disposition from birth through to adolescence make dose optimization challenging. Existing population pharmacokinetic (PopPK) models are typically developed for specific paediatric age groups, limiting their applicability across the full paediatric age range. Objectives: To develop a unified paediatric PopPK model of amikacin capable of predicting drug concentrations from birth to 18 years of age and to evaluate its suitability for model-informed dosing. Methods: Retrospective therapeutic drug monitoring data were obtained from 409 paediatric patients receiving intravenous amikacin at a tertiary children's hospital. A PopPK model was developed using data from 204 neonates, which incorporated mechanistic covariates describing growth and renal maturation, including allometric body-weight scaling, postmenstrual age (PMA), postnatal age (PNA) and age-adjusted serum creatinine. Predictive performance was evaluated for 205 older patients aged 1 month to 18 years, and compared with previously published paediatric amikacin PopPK models. The model developed using the neonatal data was subsequently refitted to the combined dataset to obtain the final parameter estimates. Results: A two-compartment model adequately described amikacin pharmacokinetics. Clearance was influenced by body weight, PMA, PNA, age-adjusted serum creatinine and concomitant glycopeptide use. The model developed in neonates using mechanistic maturation and renal function covariates successfully predicted amikacin concentrations in older paediatric patients and showed lower prediction bias and improved precision than previously published paediatric amikacin models. The final parameter estimates were obtained by fitting the model developed on neonates to all patients. Conclusions: A maturation-informed PopPK model successfully predicted amikacin concentrations from birth to 18 years and provides a unified framework for model-informed precision dosing across the paediatric age range.
- 2 April 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (8) , 772-776
Use of Cefiderocol in the Management of Children With Infection or Colonization With Multi-drug Resistant Gram-negative Bacteria: A Retrospective, Single-center Case Series
Cefiderocol, a novel siderophore cephalosporin, represents a treatment option for infections with multidrug-resistant Gram-negative bacteria, of which rates are rising worldwide. Clinical data on its use in children is limited. In our pediatric case series, the largest reported to date, cefiderocol seems safe and well tolerated, with more favorable clinical outcomes when compared to the literature reviewing adult cases.
- 2 April 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (8) , 772-776
Use of Cefiderocol in the Management of Children With Infection or Colonization With Multi-drug Resistant Gram-negative Bacteria: A Retrospective, Single-center Case Series
Cefiderocol, a novel siderophore cephalosporin, represents a treatment option for infections with multidrug-resistant Gram-negative bacteria, of which rates are rising worldwide. Clinical data on its use in children is limited. In our pediatric case series, the largest reported to date, cefiderocol seems safe and well tolerated, with more favorable clinical outcomes when compared to the literature reviewing adult cases.
- Open Access
- 7 March 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (5) , 1577-1579
SARS-CoV-2–specific T-cell responses to recurrent COVID-19 pneumonitis in a patient with post-CART B-cell aplasia
Angus Hodder, Dr, Lindsey Williams, Jan Chu, Alasdair Bamford, Charlene Rodrigues, Kimberley C Gilmour, Arnold Awuah, Fariba Tahami, Caroline Dalton, Orlagh McG
- 7 March 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (5) , 1577-1579
Open AccessSARS-CoV-2–specific T-cell responses to recurrent COVID-19 pneumonitis in a patient with post-CART B-cell aplasia
Angus Hodder, Dr, Lindsey Williams, Jan Chu, Alasdair Bamford, Charlene Rodrigues, Kimberley C Gilmour, Arnold Awuah, Fariba Tahami, Caroline Dalton, Orlagh McG